Actinomycin D downregulates Sox2 and improves survival in preclinical models of recurrent glioblastoma
Authors
Taylor, JTEllison, S
Pandele, A
Wood, S
Nathan, E
Forte, G
Parker, H
Zindy, E
Elvin, M
Dickson, A
Williams, KJ
Karabatsou, K
McCabe, Martin
McBain, Catherine A
Bigger, BW
Affiliation
Brain Tumor Research Group, Stem Cell and Neurotherapies Laboratory, Division of Cell Matrix Biology & Regenerative Medicine, University of Manchester, United Kingdom.Issue Date
2020
Metadata
Show full item recordCitation
Taylor JT, Ellison S, Pandele A, Wood S, Nathan E, Forte G, et al. Actinomycin D Downregulates Sox2 and Improves Survival in Preclinical Models of Recurrent Glioblastoma. Neuro Oncol. 2020.Journal
Neuro-OncologyDOI
10.1093/neuonc/noaa051PubMed ID
32227096Additional Links
https://dx.doi.org/10.1093/neuonc/noaa051Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1093/neuonc/noaa051